DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1948)

Atopic Dermatitis/Atopic Eczema | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Pediatric) (US)

Atopic Dermatitis/Atopic Eczema | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Pediatric) (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Atopic dermatitis (AD) disproportionately affects children and adolescents, and its intermittent flares of itchy rash profoundly affect their quality of life. Most pediatric patients use prescribed topical corticosteroids for their symptoms; systemic immunomodulators are reserved for severe refractory cases. Pfizer’s nonsteroidal topical agent Eucrisa and Sanofi/Regeneron’s Dupixent—for which we expect FDA approval for adolescent AD patients in 2019—bring new options to distinct points in the AD treatment algorithm. This claims data analysis assesses how these novel agents have begun to be integrated into patients’ treatment, as well as how they compare with the therapeutic mainstays.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric AD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric AD patients?
  • How have Dupixent and Eucrisa been integrated into the treatment algorithm for pediatric AD, and what are their sources of business?
  • What percentage of pediatric AD patients receive drug therapy within one year of diagnosis, and how quickly do they receive it? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of pediatric AD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations? What are the product-level compliance and persistency rates among drug-treated pediatric AD patients?

GEOGRAPHIES

United States

KEY DRUGS COVERED

Dupixent, Eucrisa, Protopic, Elidel, cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, topical corticosteroids

KEY ANALYSIS PROVIDED

Brand/therapy usage across a longitudinal patient sample.

Newly diagnosed patient analysis.

Treatment initiation and progression.

Line of therapy analysis.

Combination therapy analysis.

Source of business for recently treated patients.

Persistency and compliance analysis.

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (Pediatric) (US)
    • Treatment Algorithms | Atopic Dermatitis (Pediatric) | US | May 2019

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Laura Darnieder
  • Laura Darnieder is a Business Insights Analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, where she is focused on providing market forecasts within the niche biopharmaceutical space. Prior to joining DRG, Laura earned a in Neuroscience from Tufts University Sackler School of Graduate Biomedical Sciences. Her research focused on the role of stress neuropeptides and inhibitory signaling in alcohol dependence and drug addiction. She also holds a , summa cum laude, in Psychobiology and Linguistics from Binghamton University (SUNY).

Purchase Report

Recent reports:
You may also be interested in: